GNI Group Ltd.(2160) News

Disclosure of Statements Made at an Investor Conference of Gyre Therapeutics, Inc.

(Correction of Numerical Data) Partial Correction to the“Consolidated Financial Results for FY 2025 (IFRS)”

(Correction) Notice Regarding Differences in Non-Consolidated Financial Results

Notice Concerning Appointment of Directors

Notice Regarding the Execution of an Agreement for the Acquisition of Cullgen Inc. by Consolidated Subsidiary Gyre Therapeutics, Inc.

Notice Regarding the Postponement of the Disclosure of FY2026 Consolidated Earnings Forecast and Earnings Briefing

Notice Regarding Differences in Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 and the Previous Fiscal Year

Consolidated Financial Results for FY2025 (IFRS)

GNI Group, Last Fiscal Year's Net Income Turns to Loss, Current period performance is undisclosed.

Questions from Investors and Answers

Announcement Regarding Revision of Full-Year Earnings Forecast and Expected Recognition of Losses

GNI Group, Net Income Forecast for Last Fiscal Year Revised Downward to a Loss

Notice Concerning Completion of Acquisition of Shares (Conversion into a Consolidated Subsidiary) of ZOO LABO, Inc.

Cullgen’s Participation in the J.P. Morgan Healthcare Conference

Notice Regarding Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 Following Potential Eligibility for Priority Review

Notice Concerning Change in Consolidated Subsidiary (Termination of Equity Relationship)

Partial Amendment to Contractual Terms Relating to the Reverse Merger Transaction by Major Subsidiary Cullgen

Completion of Phase 1 Clinical Trial and Positive Results of CG001419, a Novel Non-Opioid Pain Product Candidate Developed by Key Subsidiary Cullgen

Q3 FY2025 Financial Results Corporate Presentation

GNI Group, Jan-Sep (Cumulative 3Q) Net Income Turns to Loss, Jul-Sep Net Income Decreases by 57%